News of Note


From the current literature

Beard C, Stason W, Wang Q, et al: Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer. Cancer 117(1):96–102, 2011.

Bookbinder M, Glajchen M, McHugh M, et al: Nurse practitioner-based models of specialist palliative care at home: Sustainability and evaluation of feasibility. J Pain Symptom Manage 41(1):25–34, 2011.

Davies A, Sitte T, Elsner F, et al: Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 41(2):358–366, 2011.

Field J, Hazinski M, Sayre M: Part I: Executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 122(18 Suppl 3):S640–S656, 2010.

Fredericks A, Hollis G, Stricker C: Diagnosis and management of opioid-induced bowel dysfunction in patients with advanced cancer. Clin J Oncol Nurs 14(6):701–704, 2011.

Irwin M, Klemp J, Glennon C, et al: Oncology nurses’ perspectives on the state of cancer survivorship care: Current practices and barriers to implementation. Oncol Nurs Forum 38(1):E11–E19, 2011.

Kim Y, Kashy D, Spillers R, et al: Needs assessment of family caregivers of cancer survivors: Th ree cohorts comparison. Psychooncology 19(6):573–582, 2010.

Kris M, Benowitz S, Adams S, et al: Clinical cancer advances 2010: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 28(36):5327–5347, 2010.

Ledermann J, Kristeleit RS: Optimal treatment for relapsing ovarian cancer. Ann Oncol 21(Suppl 7):vii218–vii222, 2010.

Masi G, Vasile E, Loupakis F, et al: Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An update analysis. J Natl Cancer Inst 103(1):21–30, 2011.

Mehnert A: Employment and work-related issues in cancer survivorship. Crit Rev Oncol Hematol 77(2):109–130, 2011.

Mitchell A, Chan M, Bhatti H, et al: Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies. Lancet Oncol 12(2):160–174, 2011.

Morgan C, Tillett T, Braybrooke J, et al: Management of uncommon chemotherapy-induced emergencies. Lancet Oncol January 26, 2011. Epub ahead of print.

Palos G, Mendoza T, Liao K, et al: Caregiver symptom burden: The risk of caring for an underserved patient with advanced cancer. Cancer 117(5):1070–1079, 2011.

Porter L, Keefe F, Garst J, et al: Caregiver-assisted coping skills training for lung cancer: Results of a randomized clinical trial. J Pain Symptom Manage 41(1):1–13, 2011.

Rayner L, Price A, Hotopf M, et al: The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer 47(5):702–712, 2011.

Taylor S, Harley C, Campbell L, et al: Discussion of emotional and social impact of cancer during outpatient oncology consultations. Psychooncology 20(3):242–251, 2011.

Turaga K, Malafa M, Jacobsen P, et al: Suicide in patients with pancreatic cancer. Cancer 117(3):642–647, 2011.

van Ryn M, Sanders S, Kahn K, et al: Objective burden, resources and other stressors among informal cancer caregivers: A hidden quality issue? Psychooncology 20(1):44–52, 2011.

Wood J, Chapman K, Eilers J: Tools for assessing nausea, vomiting and retching: A literature review. Cancer Nurs 34(1):E14–E24, 2011.

Related Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
Related Content